← All trials
NCT05296629
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Mar 25, 2022
- Last posted
- May 10, 2022
- Enrollment
- 320
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fortress BiotechLead sponsor
- Fortress BiotechStudy director
- Dr. Reddy's LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.